305 related articles for article (PubMed ID: 25767619)
1. Theranostic impact of NG2/CSPG4 proteoglycan in cancer.
Nicolosi PA; Dallatomasina A; Perris R
Theranostics; 2015; 5(5):530-44. PubMed ID: 25767619
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers.
Zhang H; Wu Z; Hu D; Yan M; Sun J; Lai J; Bai L
Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891187
[TBL] [Abstract][Full Text] [Related]
3. Chondroitin Sulphate Proteoglycan 4 (NG2/CSPG4) Localization in Low- and High-Grade Gliomas.
Mellai M; Annovazzi L; Bisogno I; Corona C; Crociara P; Iulini B; Cassoni P; Casalone C; Boldorini R; Schiffer D
Cells; 2020 Jun; 9(6):. PubMed ID: 32599896
[TBL] [Abstract][Full Text] [Related]
4. Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
Hsu SC; Nadesan P; Puviindran V; Stallcup WB; Kirsch DG; Alman BA
J Biol Chem; 2018 Feb; 293(7):2466-2475. PubMed ID: 29196603
[TBL] [Abstract][Full Text] [Related]
5. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
[TBL] [Abstract][Full Text] [Related]
6. Diversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsets.
Girolamo F; Dallatomasina A; Rizzi M; Errede M; Wälchli T; Mucignat MT; Frei K; Roncali L; Perris R; Virgintino D
PLoS One; 2013; 8(12):e84883. PubMed ID: 24386429
[TBL] [Abstract][Full Text] [Related]
7. Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma.
Wang J; Svendsen A; Kmiecik J; Immervoll H; Skaftnesmo KO; Planagumà J; Reed RK; Bjerkvig R; Miletic H; Enger PØ; Rygh CB; Chekenya M
PLoS One; 2011; 6(7):e23062. PubMed ID: 21829586
[TBL] [Abstract][Full Text] [Related]
8. Structural deciphering of the NG2/CSPG4 proteoglycan multifunctionality.
Tamburini E; Dallatomasina A; Quartararo J; Cortelazzi B; Mangieri D; Lazzaretti M; Perris R
FASEB J; 2019 Mar; 33(3):3112-3128. PubMed ID: 30550356
[TBL] [Abstract][Full Text] [Related]
9. The regulatory mechanisms of NG2/CSPG4 expression.
Ampofo E; Schmitt BM; Menger MD; Laschke MW
Cell Mol Biol Lett; 2017; 22():4. PubMed ID: 28536635
[TBL] [Abstract][Full Text] [Related]
10. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.
Wang Y; Geldres C; Ferrone S; Dotti G
Expert Opin Ther Targets; 2015; 19(10):1339-50. PubMed ID: 26190756
[TBL] [Abstract][Full Text] [Related]
11. The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas.
Schiffer D; Mellai M; Boldorini R; Bisogno I; Grifoni S; Corona C; Bertero L; Cassoni P; Casalone C; Annovazzi L
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30213051
[TBL] [Abstract][Full Text] [Related]
12. Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.
Kurokawa T; Imai K
Proc Jpn Acad Ser B Phys Biol Sci; 2024; 100(5):293-308. PubMed ID: 38735753
[TBL] [Abstract][Full Text] [Related]
13. NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion.
Cattaruzza S; Nicolosi PA; Braghetta P; Pazzaglia L; Benassi MS; Picci P; Lacrima K; Zanocco D; Rizzo E; Stallcup WB; Colombatti A; Perris R
J Mol Cell Biol; 2013 Jun; 5(3):176-93. PubMed ID: 23559515
[TBL] [Abstract][Full Text] [Related]
14. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.
Price MA; Colvin Wanshura LE; Yang J; Carlson J; Xiang B; Li G; Ferrone S; Dudek AZ; Turley EA; McCarthy JB
Pigment Cell Melanoma Res; 2011 Dec; 24(6):1148-57. PubMed ID: 22004131
[TBL] [Abstract][Full Text] [Related]
15. CSPG4: a prototype oncoantigen for translational immunotherapy studies.
Rolih V; Barutello G; Iussich S; De Maria R; Quaglino E; Buracco P; Cavallo F; Riccardo F
J Transl Med; 2017 Jul; 15(1):151. PubMed ID: 28668095
[TBL] [Abstract][Full Text] [Related]
16. NG2/CSPG4 regulates cartilage degeneration during TMJ osteoarthritis.
Reed DA; Zhao Y; Bagheri Varzaneh M; Shin JS; Rozynek J; Miloro M; Han M
Front Dent Med; 2022; 3():. PubMed ID: 36685663
[TBL] [Abstract][Full Text] [Related]
17. CD44 adhesion molecule and neuro-glial proteoglycan NG2 as invasive markers of glioma.
Wiranowska M; Ladd S; Smith SR; Gottschall PE
Brain Cell Biol; 2006 Jun; 35(2-3):159-72. PubMed ID: 17957481
[TBL] [Abstract][Full Text] [Related]
18. NG2/CSPG4 attenuates motility in mandibular fibrochondrocytes under serum starvation conditions.
Ahn SY; Bagheri Varzaneh M; Zhao Y; Rozynek J; Ravindran S; Banks J; Chaudhry M; Reed DA
Front Cell Dev Biol; 2023; 11():1240920. PubMed ID: 38020894
[TBL] [Abstract][Full Text] [Related]
19. Functional and clinical relevance of chondroitin sulfate proteoglycan 4.
Campoli M; Ferrone S; Wang X
Adv Cancer Res; 2010; 109():73-121. PubMed ID: 21070915
[TBL] [Abstract][Full Text] [Related]
20. NG2 proteoglycan increases mesangial cell proliferation and extracellular matrix production.
Xiong J; Wang Y; Zhu Z; Liu J; Wang Y; Zhang C; Hammes HP; Lang F; Feng Y
Biochem Biophys Res Commun; 2007 Oct; 361(4):960-7. PubMed ID: 17686464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
